Search Results
Your search for ,HOW matches 8288 pages
Showing 151 - 200My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Jobs Commonly Held by Immigrant Women May Put Them at Increased Risk for Breast Cancer
Many immigrant women in the United States work in jobs that may expose them to chemicals linked to breast cancer, according to a recent study led by Silent Spring Institute. The analysis is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among...
Raajit K. Rampal, MD, PhD, on Managing Anemia and Thrombocytopenia in Patients With Myelofibrosis
Raajit K. Rampal, MD, PhD, Director of the Center for Hematologic Malignancies and the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses management strategies for these two conditions often associated with myelofibrosis. He discusses the role of Janus kinase...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Elironrasib Active in KRAS G12C–Resistant NSCLC
Elironrasib, a novel RAS G12C–selective tri-complex inhibitor, demonstrated initial clinical activity and a differentiated safety profile in heavily pretreated patients with non–small cell lung cancer (NSCLC) and KRAS G12C mutations, according to findings from a phase I trial presented at the 2025...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
President Biden Completes Radiation Therapy Course
President Joe Biden has completed his course of radiation therapy for prostate cancer, which he recently marked by ringing the ceremonial bell alongside his radiation oncology care team. According to a report from People, President Biden’s daughter Ashley Biden shared the moment on her Instagram...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus
The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on surveillance of Barrett’s esophagus, the only known precursor to esophageal adenocarcinoma. The new guideline, which was published in Gastroenterology, emphasizes risk-based, individualized...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
Significant Overall Survival Benefit With Enzalutamide Plus Leuprolide for Biochemically Recurrent Prostate Cancer
Enzalutamide in combination with leuprolide demonstrated a significantly longer overall survival than either leuprolide or enzalutamide monotherapy in patients with biochemically recurrent prostate cancer, according to the final overall survival analysis of the phase III EMBARK trial presented at...
New AACI President-Elect Selected; Two Cancer Center Leaders Join Board
Cornelia Ulrich, MS, PhD, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Ulrich is Chief Scientific Officer and Executive Director of the Comprehensive Cancer Center at Huntsman...
10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer
At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for human papillomavirus (HPV)–associated oropharyngeal cancers was 1.74%, according to findings culled from the Cleveland Clinic Cancer Institute database. These...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer
In a prospective cohort study published in JCO Oncology Practice, Ssebyala et al examined long-term health-care utilization and adherence to follow-up care among young adult survivors of breast cancer. Their findings reveal high rates of mammography adherence but persistent gaps in other areas of...
Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression
New research revealed that depression can impact surgical outcomes, making it more difficult for patients to recover from surgery, thus leading to higher postoperative costs as well. In patients with gastrointestinal cancers and depression who were undergoing surgery specifically, antidepressants...
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
When seeking a surgeon for treatment, providing emotional support and helping patients manage expectations are among the top areas of communication valued by patients, according to a recent systematic review. The research was presented at the 2025 American College of Surgeons (ACS) Clinical...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...
Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress, Survey Finds
The process of obtaining insurance prior authorization before a medical procedure, service, or medication prescription has typically been left to clinicians. However, as cancer therapies grow increasingly complex, the burden of navigating insurance prior authorization is increasingly being shared...
Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers
Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatments, including biologics or radiation therapy. An analysis by Joseph M. Unger, PhD, MS, Professor,...
Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste
A new study found that implementing a network of cancer drug repositories (CDRs) improved access to cancer medications and eliminated unnecessary medication waste by allowing people to donate unopened or unused medications that would otherwise be wasted. This resulted in patients with cancer...
Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer
Clinically meaningful improvements in longer-term quality of life were achieved with the addition of atezolizumab immunotherapy to chemoradiation in patients with limited-stage small cell lung cancer (LS-SCLC), according to patient-reported outcome findings from the NRG LU005 trial presented during ...
9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers
A recent study has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against...
Cytogenetic Remission Linked to Improved Survival in Patients With AML
Patients with acute myeloid leukemia (AML) who achieve cytogenetic remission may have better survival outcomes than patients with new or sustained cytogenetic abnormalities, according to findings from a study published in the American Journal of Hematology. The study elucidated how cytogenetic...
In Extensive-Stage Small Cell Lung Cancer, Novel Maintenance Regimen Boosts Overall Survival
The phase Ib DeLLphi-303 trial has reported overall survival data for a novel maintenance regimen in extensive-stage small cell lung cancer following first-line chemoimmunotherapy. Patients treated with the bispecific T-cell engager tarlatamab-dlle plus a PD-L1 inhibitor had a median overall...
Bijal Shah, MD, on CAR T-Cell Therapy in ALL
Bijal Shah, MD, of Moffitt Cancer Center, summarizes his presentation on the role of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), touching on its use in the front-line setting for newly diagnosed patients with high risk-features as well as in patients with...
Impact of Proton and Photon Therapies on HRQOL in Breast Cancer
Health-related quality-of-life measurements demonstrated that both proton and photon radiation therapies led to excellent and similar impacts on quality of life for patients with breast cancer undergoing comprehensive nodal irradiation, according to findings from the phase III RadComp trial that...
Anthony Letai, MD, PhD, Takes the Helm as New NCI Director
Anthony Letai, MD, PhD, was sworn in on September 29 as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), by Health and Human Services Secretary Robert F. Kennedy, Jr. Dr. Letai takes the helm of the world’s most prestigious cancer research agency...
Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...
Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International. “This type of cancer, which is a result of...
More Tattoos, Lower Risk of Melanoma? New Study Investigates
People with more than one tattoo session may have a decreased risk of developing melanoma—with one key caveat, according to research published by McCarty et al in the Journal of the National Cancer Institute. A team led by Jennifer Doherty, PhD, Huntsman Cancer Institute investigator, Co-Leader of ...
HPV Self-Sampling Collection Test Improved Cervical Cancer Screening Rates Among Asian American Women
Studies have shown that human papillomavirus (HPV) infection—especially with high-risk variants such as HPV16 and HPV18—is the primary cause of cervical cancer, accounting for about 95% of all cases. Although cervical cancer screening through Pap smear tests can detect the presence of precancerous...
Surgery for Early-Stage Cancer and Opioid Use
Curative-intent surgery for patients with early-stage cancer led to new, persistent, long-term opioid use in more than 1 in 10 opioid-naive veterans, according to the results of an observational study published in Cancer. The results of the study highlighted how necessary it is to develop new pain...
James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69
James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical complications from surgery in...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
The 15th edition of the annual AACR Cancer Progress Report presents a mixed picture of the major advances in cancer care over the past year, including the approval of 20 new anticancer drugs, juxtaposed against the continuing rise in early-onset cancers and disparities in care as well as the...
Overall Survival Benefit Shown for Neoadjuvant Nivolumab Plus Chemotherapy in Non–Small Cell Lung Cancer
In the preplanned final analysis of the phase III CheckMate 816 trial, an overall survival benefit has been shown for neoadjuvant nivolumab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).1 Patients treated with the combination experienced an approximate 10%...
Oral Microbiota and Risk for Pancreatic Cancer
Investigators have found several oral bacteria and fungi associated with an increased risk for pancreatic cancer, according to findings published in JAMA Oncology. This cohort study seems to confirm a long-standing suspicion of the relationship between poor oral health and pancreatic cancer and...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy
Three leading national cancer organizations have issued an updated guideline on postmastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight...
